



Abraxane® (paclitaxel, protein-bound) – First-time authorized brand alternative

- On April 12, 2022, [Apotex](#) and [TWi Pharmaceuticals](#) launched authorized brand alternatives of Abraxis BioScience's [Abraxane \(paclitaxel, protein-bound\)](#) injection.
- Abraxane is approved for the treatment of metastatic breast cancer, non-small cell lung cancer and adenocarcinoma of the pancreas.
- Abraxane carries a boxed warning for severe myelosuppression.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.